GlassScriptPhysician profile
Stacy Y Kasitinon
NPI 1467030023
$3,880.25
in general payments reported to CMS, 2019-2025
20 companies · $1,988 in 2025
The $1,988 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $221 · 2024: $1,671 · 2025: $1,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,541 · Education: $99.99 · Travel and Lodging: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,540.80 |
| Education | $99.99 |
| Travel and Lodging | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $773.98 | 2024-2025 | |
| Galderma Laboratories, L.P. | $433.51 | 2024-2025 | Nemluvio |
| Genzyme Corporation | $415.22 | 2024-2025 | |
| Ucb, INC. | $311.74 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $276.80 | 2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.81 | 2024-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $180.78 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $165.60 | 2025 | |
| Amgen INC. | $159.86 | 2024-2025 | Otezla, Otezla |
| Lilly USA, LLC | $154.34 | 2024-2025 | Olumiant, Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $137.28 | 2025 | Dupixent, Libtayo |
| Blueprint Medicines Corporation | $123.26 | 2025 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $121.91 | 2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $50.20 | 2025 | |
| Incyte Corporation | $41.36 | 2025 | Opzelura |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $38.60 | 2025 | |
| Botanix Sb INC | $33.76 | 2025 | Sofdra |
| Leo Pharma INC. | $24.77 | 2025 | Anzupgo |
| Fidia Pharma USA INC. | $19.26 | 2025 | |
| Sun Pharmaceutical Industries INC. | $14.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Kasitinon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.